MINI FUTURE SHORT - ELI LILLY & CO | Market Closed - Swiss Exchange 11:20:00 2024-05-27 am EDT | ||
| 1.08 CHF | -0.92% |
|
| Current month | -25.00% | ||
| 1 month | -39.66% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-05-27 | 1.08 | -0.92% |
| 24-05-24 | 1.09 | +1.87% |
| 24-05-23 | 1.07 | -8.55% |
| 24-05-22 | 1.17 | +2.63% |
| 24-05-21 | 1.14 | -19.72% |
Delayed Quote Swiss Exchange
Last update May 27, 2024 at 11:20 am EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| VXTABP | |
| ISIN | CH1332894406 |
| Date issued | 2024-03-22 |
| Strike | 927.9 $ |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | - CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 1.88 CHF |
|---|---|
| Lowest since issue | 1.07 CHF |
| Spread | 0.03 CHF |
| Spread % | 2.78% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
807.4
USD
Average target price
850.8
USD
Spread / Average Target
+5.37%
- Stock Market
- Certificates
- VXTABP Certificat
